Here, we present a summary of a health economics analysis plan being undertaken to the second part of the Repurposing anti-TNF for treating Dupuytren’s disease (RIDD) trial, which targets patients with early stage DD. This evidence concerns the gene TNF and Dupuytren Contracture.